Kazia Therapeutics Changes ADS to Ordinary Share Ratio
Ticker: KZIA · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ADS-ratio-change, disclosure, corporate-action
TL;DR
Kazia is changing its ADS ratio from 1:10 to 1:100, effective Oct 2024.
AI Summary
Kazia Therapeutics Limited announced on October 15, 2024, a change in the ratio of its American Depositary Shares (ADSs) to Ordinary Shares. The ratio will change from one ADS representing ten Ordinary Shares to one ADS representing one hundred Ordinary Shares. This adjustment is effective for the month of October 2024.
Why It Matters
This ratio change can impact the trading price and liquidity of the ADSs, potentially making them more accessible to a wider range of investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a change in the ADS ratio, which is a common corporate action and does not inherently indicate financial distress or significant operational changes.
Key Numbers
- 1:10 — Old ADS to Ordinary Share Ratio (Previous ratio before the change.)
- 1:100 — New ADS to Ordinary Share Ratio (New ratio effective October 2024.)
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- American Depositary Shares (ADSs) (security) — Ratio change subject
- Ordinary Shares (security) — Ratio change subject
- October 2024 (date) — Effective period
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a change in the ratio of Kazia Therapeutics Limited's American Depositary Shares (ADSs) to Ordinary Shares.
What was the previous ratio of ADSs to Ordinary Shares?
The previous ratio was one (1) ADS representing ten (10) Ordinary Shares.
What is the new ratio of ADSs to Ordinary Shares?
The new ratio is one (1) ADS representing one hundred (100) Ordinary Shares.
When is this change in ratio effective?
The change is effective for the month of October 2024.
What is the company's principal executive office address?
The principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 17.2 · Accepted 2024-10-15 07:01:54
Key Financial Figures
- $1.00 — ompliance with the minimum bid price of $1.00 per share as outlined in the Nasdaq Lis
Filing Documents
- d726235d6k.htm (6-K) — 12KB
- 0001193125-24-237190.txt ( ) — 13KB
Forward-Looking Statements
Forward-Looking Statements Certain as such by the use of words such as may, will, estimate, future, forward, anticipate, or other similar words. Any statement describing Kazias future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forwardlooking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazias clinical and preclinical trials, Kazias strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, the potential market opportunity for paxalisib, and the ADS Ratio Change. Such statements are based on Kazias current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazias Annual Report, filed on form 20-F with the United States Securities and Exchange Commission (the SEC), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this report.